NxStage Medical Lifts Q4, FY14 Revenue Forecast - Quick Facts

(RTTNews) - NxStage Medical, Inc. (NXTM), a manufacturer of innovative dialysis products, Tuesday increased its revenue guidance for the fourth quarter and fiscal year ended December 31, 2014.

For the fourth quarter, the company expects to deliver total revenue above $78 million, exceeding the top end of its previously announced guidance range of $74.5 million to $76.5 million. This performance is expected to reflect above 18 percent growth in the Home, compared to the fourth quarter of 2013. Wall Street looks for quarterly revenues of $75.75 million.

For 2014, the company expects to deliver total revenue above $299 million, exceeding the top end of its guidance of $296 million to $298 million. Annual Home revenue growth for 2014 is expected to be about 18 percent, exceeding the company's previously announced guidance of 15 percent growth. Analysts expect annual revenues of $297.31 million.

The company also expects net loss for the fourth quarter and 2014 to be at the favorable end of its previously announced guidance ranges of $5 million to $7 million and $24 to $26 million, respectively.

"Heading into 2014, we detailed a clear strategy to accelerate growth and adoption in the Home. We solidly executed against this strategy, delivering greater than 15% growth in Home within each quarter and ending the year well ahead of our 15% annual growth target," said Jeffrey Burbank, Chief Executive Officer.